CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis
Eileen O’Meara(Montreal Heart Institute), Bruce Sussex(Memorial University of Newfoundland), Gordon W. Moe(Deleted Institution), Olivier Desplantie(Royal Jubilee Hospital), Justin A. Ezekowitz(University of Alberta), Nowell M. Fine(University of Calgary), Adrian F. Hernandez(Duke University), Anique Ducharme(Montreal Heart Institute), Heather J. Ross(University of Toronto), George Heckman(University of Waterloo), David Z.I. Cherney(University Health Network), Anita Asgar(Montreal Heart Institute), Abdul Al‐Hesayen(St. Michael's Hospital), Adam Grzeslo(Hamilton Health Sciences), Marie-Hélène Leblanc, E. Estrella-Holder(St. Boniface Hospital), Simon Kouz, Elizabeth Swiggum(University of British Columbia), Michael McDonald(University Health Network), Miroslaw Rajda(Dalhousie University), Margot K. Davis(University of British Columbia), Douglas S. Lee(University of Toronto), Lee A. Green(University at Buffalo, State University of New York), Karen Harkness(Hamilton Health Sciences), Robert S. McKelvie(McMaster University Medical Centre), Sylvain Matteau(Université de Sherbrooke), Gideon Cohen(Sunnybrook Health Science Centre), Sheri L. Koshman(University of Alberta), Marie-Claude Parent(Montreal Heart Institute), Nadia Giannetti(Inserm), Alain Cohen‐Solal(Inserm), Mustafa Toma, Subodh Verma(St. Michael's Hospital), Shelley Zieroth(University of Manitoba), Sabe De(Western University), Howard Abrams(University Health Network), Frederick A. Masoudi(Bristol-Myers Squibb (United States)), Michel D’Astous(Dr. Georges-L.-Dumont University Hospital Centre), Sean Virani(University of British Columbia), Haissam Haddad(St. Michael's Hospital), Michael Chan(University of Alberta), Diego Delgado(Toronto General Hospital), Jonathan G. Howlett(University of Calgary), Lisa Mielniczuk(University of Ottawa), Serge Lepage
Cited by 121
Related Papers
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
|Hypertension|2003|13.3k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction
|Circulation|2010|4.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k